Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community

NCT06704204 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

HIV

Interventions

DRUG: The first FDA-approved LAI ART regimen includes an integrase inhibitor, cabotegravir (CAB), and a non-nucleoside reverse transcriptase inhibitor, rilpivirine (RPV) combined 4 wks

Sponsor

The Miriam Hospital

Collaborators

[object Object]